ADoTope MC003
/ Medicovestor
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 03, 2025
MC003: ADoTope, a first-in-class dual-payload bi-epitope combination chemoimmunotherapy antibody drug conjugate (ADC) targeting folate receptor alpha in platinum-resistant epithelial ovarian cancer
(SITC 2025)
- "While the FDA has approved mirvetuximab soravtansine for platinum-resistant ovarian cancer, its clinical performance underscores a persistent unmet need in this highly refractory population. Our data provides preclinical support for the ADoTope platform and justifies advancing MC003 to further development for platinum-resistant ovarian cancer treatment. MC003 is currently in IND-enabling stage of development.Ethics Approval All animal experiments were carried out under the Sanyou Biopharmaceuticals Laboratory Animal Ethics Committee.Abstract 995 Figure 1Request permissions"
IO biomarker • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1
October 13, 2025
MC003: ADoTope, a first-in-class dual-payload bi-epitope combination chemoimmunotherapy antibody drug conjugate (ADC) targeting Folate Receptor Alpha (FRa) in platinum-resistant epithelial ovarian cancer.
(AACR-NCI-EORTC 2025)
- "While the FDA has approved mirvetuximab soravtansine for platinum-resistant ovarian cancer, its clinical performance underscores a persistent unmet need in this highly refractory population. Our data provides preclinical support for the ADoTope platform and justifies advancing MC003 to further development for platinum-resistant ovarian cancer treatment. MC003 is currently in IND-enabling stage of development."
IO biomarker • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1
1 to 2
Of
2
Go to page
1